Compare MCK & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCK | REGN |
|---|---|---|
| Founded | 1833 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0B | 73.2B |
| IPO Year | 1995 | 1995 |
| Metric | MCK | REGN |
|---|---|---|
| Price | $797.34 | $617.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 25 |
| Target Price | ★ $952.92 | $830.16 |
| AVG Volume (30 Days) | 935.8K | ★ 1.1M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | 0.40% | ★ 0.55% |
| EPS Growth | ★ 49.22 | 8.19 |
| EPS | ★ 38.38 | 6.75 |
| Revenue | ★ $112,084,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $14.94 | $12.45 |
| Revenue Next Year | $8.21 | $10.13 |
| P/E Ratio | ★ $20.59 | $89.08 |
| Revenue Growth | 3.11 | ★ 20.82 |
| 52 Week Low | $637.00 | $503.25 |
| 52 Week High | $999.00 | $821.11 |
| Indicator | MCK | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 39.68 |
| Support Level | $796.22 | $610.60 |
| Resistance Level | $846.29 | $618.01 |
| Average True Range (ATR) | 15.48 | 15.83 |
| MACD | 8.93 | 2.17 |
| Stochastic Oscillator | 96.25 | 45.16 |
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.